Author: crjfinlayson

Shipped to existing Customer with operations in the U.K. and the E.U. THC-free broad-spectrum distillate from a single cultivar is a superior core formulation for nutraceutical and cosmetic formulations. PharmaCielo is among the few global producers that deliver broad-spectrum formulations produced from specially selected, developed

Colombian and Mexican GMP certifications expected during Q1'21 and Q2'21, respectively The Company confirms that its recently completed Processing and Extraction Center at its Rionegro facility, Colombia's largest scale processing centre, will be producing extracts in compliance with EU-GMP guidelines by the end of February. TORONTO and RIONEGRO, Colombia,

Alliance with AssuredTrans, Inc. will enable PharmaCielo to provide up-front independent laboratory analysis and insurance of its recently expanded product portfolio to potential customers in the U.S., beginning in 2021 Former congressman notes alliance enables U.S. customers to have confidence in the purity and quality

Loan of COP$8.5 billion (approximately CDN$3.0 million1) has an 84-month term, 10.14% coupon and revolving component with no equity dilution This loan together with the proceeds of the recent CDN$10mm equity financing put the company in a well-capitalized position to execute on its growing sales

PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis From Narcotic Drugs List TORONTO, Canada (December 3, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“PharmaCielo Holdings”), commends

December 20, 2020 By Dana Rohrabacher, former U.S. Congressman and PharmaCielo Advisor Here at home-base USA and throughout the world, major changes in the status of cannabis can be expected in the year ahead. After decades of senseless debate and destructive enforcement, there is now

Effective December 1, Henning von Koss has been named CEO of PharmaCielo, replacing departing CEO David Attard. Successful achievement of Q3 operational milestones: Processing and Extraction Centre (“PEC”) construction completed – one of largest current extraction footprints[1] globally; expanded product portfolio launched Plan to initiate

David Attard and Board of Directors reach mutual agreement under which David will step down as Chief Executive Officer and PharmaCielo board member, effective December 1st, 2020. Henning von Koss, currently President and a member of PharmaCielo’s Board of Directors, formerly with Bayer and 30-year

Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO, Canada and RIONEGRO, Colombia (November 25, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the

TORONTO, Ontario (November 23, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF) is pleased to announce the closing of its previously announced private placement of units ("Units") of the Company for gross proceeds of $10.0 million. “The closing of this offering further strengthens the Company’s balance sheet